Fluoxetine Delivery for Wound Treatment Through an Integrated Bioelectronic Device - Pharmacokinetic Parameters and Safety Profile in Swine

This study demonstrates that an integrated bioelectronic iontophoresis device delivers fluoxetine to porcine wounds more effectively than topical bolus dosing, achieving higher local tissue concentrations and sustained antibacterial levels without systemic absorption or adverse effects.

The Gist

Imagine you have a deep, stubborn cut on your skin that just won't heal. Maybe it's infected, or maybe it's just stuck in a cycle of inflammation. Doctors usually treat this with antibiotics, but bacteria are getting smarter and resisting those drugs. So, scientists are looking for "old" drugs with "new" jobs. One of these is Fluoxetine (better known as Prozac), a common antidepressant.

It turns out that Fluoxetine doesn't just help with mood; it also acts like a "super-charger" for wound healing and a "stop sign" for bad bacteria. But there's a catch: if you just squirt it on a wound like ketchup on a burger (a "bolus" dose), it doesn't work very well. It washes away, doesn't soak deep enough, and you'd need to use so much of it that it might get into your bloodstream and cause side effects.

This paper is about a high-tech, smart bandage designed to solve that problem. Here is the story of how they tested it, explained simply:

1. The Problem: The "Sponge" vs. The "Spray"

Think of a wound like a dry sponge.

• The Old Way (Bolus Dosing): If you pour a cup of water (the drug) over a sponge all at once, most of it runs off the sides or evaporates before the sponge can really drink it up. You end up with a wet surface but a dry core.
• The New Way (The Bioelectronic Device): Imagine a smart water dispenser that drips water slowly, steadily, and precisely into the sponge, right where it needs to go, over many hours. The sponge soaks it all up.

The researchers built a wearable bandage that acts like that smart dispenser. It uses electricity (iontophoresis) to gently push the Fluoxetine molecules deep into the wound tissue, rather than just letting them sit on top.

2. The Test: The Piggy Bank Experiment

To see if this worked, they used pigs (because pig skin is very similar to human skin). They created several wounds on each pig and treated them in different ways:

• Group A: Got the drug poured on them with a pipette (the "spray" method).
• Group B: Got the drug delivered by the new smart bandage (the "drip" method).
• Group C: Got nothing or just salt water (the control).

They measured how much drug ended up inside the actual tissue of the wound.

The Result: The smart bandage was a winner. It delivered four times more drug into the tissue than the pipette method, even though they used the same total amount of medicine. It was like the bandage was a master key that unlocked the door for the medicine, while the pipette just knocked on the door.

3. The Safety Check: Is it leaking into the bloodstream?

Since Fluoxetine is a brain drug, the researchers were worried: If we put it on a wound, will it travel to the brain and make the pig depressed or change its heart rate?

They checked the pigs' blood (plasma) like a security guard checking a passport.

• The Finding: Zero. They couldn't find a single trace of the drug in the blood.
• The Metaphor: It's like putting a strong-smelling perfume in a sealed jar. The jar (the wound) smells great, but the room (the rest of the body) smells like nothing. The drug stayed exactly where it was supposed to be.

4. The "Goldilocks" Effect on Serotonin

Fluoxetine works by messing with serotonin (a chemical that helps cells talk to each other).

• In the brain, it stops serotonin from being re-absorbed, making you feel better.
• In the skin, serotonin helps cells move to close the wound and tells immune cells to calm down.

The researchers found something interesting:

• Too much drug: The wound got so much Fluoxetine that it actually stopped the local serotonin from doing its job.
• Just the right amount (The "Goldilocks" zone): The smart bandage delivered a moderate amount that made the local serotonin levels go up, which is exactly what you want to speed up healing.

5. The "Smart" Future

This isn't just a bandage; it's a computerized doctor on your skin.

• It has a tiny camera inside that takes pictures of the wound.
• It can be controlled wirelessly from a laptop.
• In the future, it could use Artificial Intelligence to look at the wound, say, "Oh, this part is infected, I need more antibiotic," or "This part is healing, I need to slow down the drug."

The Bottom Line

This study shows that we can take an old drug (Fluoxetine) and give it a new superpower by using a smart, electric bandage.

• Better: It gets more medicine into the wound.
• Safer: It doesn't leak into the rest of the body.
• Smarter: It can be programmed to give the exact right dose at the exact right time.

It's a step toward a future where treating a wound isn't just about slapping on a bandage and hoping for the best, but about using technology to actively manage the healing process, one precise drop at a time.

Technical Summary

1. Problem Statement

Wound infections are a major healthcare burden, often leading to chronic wounds or systemic infections. The rise of antimicrobial resistance necessitates alternative treatment strategies. While Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine have shown promise as repurposed drugs with both antimicrobial (anti-biofilm) and pro-healing properties, current delivery methods (e.g., topical bolus/pipette dosing) suffer from inefficiencies:

• Low Tissue Concentration: Conventional topical application often fails to achieve therapeutic concentrations required to inhibit bacterial growth (Minimum Inhibitory Concentration, MIC).
• Lack of Control: Manual dosing lacks the precision to maintain optimal drug levels over time.
• Safety Concerns: There is a need to ensure that topical application does not lead to systemic absorption, which could cause off-target effects (e.g., altering systemic serotonin levels or drug-drug interactions).

2. Methodology

The study utilized a porcine excisional wound model (Yorkshire-Landrace-Duroc crossbreed pigs) to compare two delivery methods:

• Experimental Device: A programmable, wirelessly controlled, wearable bioelectronic device.
  • Mechanism: Uses a voltage-driven iontophoresis pump actuator embedded in a Polydimethylsiloxane (PDMS) base. It utilizes hydrogel ion-exchange membranes within glass capillaries to selectively deliver fluoxetine ions into the wound bed.
  • Control: Controlled remotely via a laptop using a custom software interface. It supports real-time monitoring via an integrated high-resolution camera and allows for precise, temporally controlled dosing (e.g., 0.45 mg/wound/day over 6, 12, or 22-hour windows).
• Control Method: Conventional topical bolus dosing using a pipette to apply fluoxetine solution directly to the wound.

Experimental Design:

• Groups: Pigs received fluoxetine via the device or pipette at "high" (0.45 mg/wound/day) and "low" (0.025 mg/wound/day) doses.
• Duration: Treatments were administered daily for 3, 7, or 10 days.
• Sampling:
  • Wound Tissue: Excised at various time points to measure fluoxetine concentration and half-life.
  • Plasma: Collected to detect systemic fluoxetine, norfluoxetine (metabolite), and serotonin levels.
• Analysis: High-Performance Liquid Chromatography (HPLC) with UV absorbance and electrochemical detection was used to quantify drug levels and serotonin.

3. Key Contributions

• Novel Delivery System: Development and validation of a closed-loop capable, wirelessly controlled bioelectronic device for precise iontophoretic delivery of SSRIs to wounds.
• Pharmacokinetic (PK) Profiling: First establishment of fluoxetine pharmacokinetic parameters (specifically half-life) in porcine wound tissue.
• Safety Validation: Comprehensive assessment of systemic absorption and the impact on the serotonin system, confirming the safety of topical application.
• Dose Optimization: Demonstration that metered device delivery achieves therapeutic concentrations at lower cumulative doses compared to bolus dosing.

4. Key Results

A. Enhanced Tissue Concentration

• Device vs. Bolus: The bioelectronic device resulted in significantly higher fluoxetine concentrations in wound tissue compared to pipette bolus dosing (p=0.0041).
• Peak Levels: The device achieved a maximum concentration of 12.25 ng fluoxetine per mg tissue, whereas bolus dosing only reached 2.926 ng/mg.
• Therapeutic Relevance: The device-delivered concentrations exceeded the Minimum Inhibitory Concentration (MIC) for certain clinically important bacteria (e.g., A. baumannii) and were sufficient to produce synergistic killing with antibiotics against multidrug-resistant strains.

B. Pharmacokinetics

• Half-Life: The elimination half-life ($T_{1/2}$) of fluoxetine in wound tissue was calculated to be 0.988 ± 0.256 days. This suggests that once-daily application is optimal to maintain steady-state therapeutic levels without accumulation.
• Correlation: Tissue fluoxetine levels were strongly correlated with the cumulative dose delivered by the device.

C. Safety and Systemic Absorption

• Systemic Absorption: Fluoxetine and its active metabolite, norfluoxetine, were not detected in the plasma of any pig (detection limits: 7.4 ng/mL and 6.9 ng/mL, respectively).
• Serotonin Levels:
  • Systemic: Topical application did not alter systemic plasma serotonin levels.
  • Local: Wound tissue serotonin levels increased in the presence of intermediate fluoxetine concentrations but not at high concentrations, suggesting a dose-dependent modulation of local serotonin signaling beneficial for healing.

5. Significance and Conclusion

This study demonstrates that an integrated bioelectronic device can effectively overcome the limitations of conventional topical drug delivery for wound care.

• Clinical Impact: The device allows for the delivery of fluoxetine at concentrations sufficient to combat infection (anti-biofilm/antibacterial) and promote healing (pro-reparative) while minimizing the total drug load required.
• Safety Profile: The lack of systemic absorption and unchanged plasma serotonin levels indicate a high safety margin, reducing the risk of side effects associated with oral SSRIs.
• Future Applications: The device's programmable nature and integrated imaging capabilities pave the way for closed-loop, AI-driven wound care. Future iterations could automatically adjust dosing based on the wound's healing stage (hemostasis, inflammation, proliferation, maturation), optimizing treatment adherence and efficacy for both infected and non-infected chronic wounds.

In summary, the research validates a new paradigm for wound management: precision bioelectronic delivery of repurposed drugs that is more effective, safer, and more adaptable than traditional manual application.